EU Panel Backs Pembrolizumab Plus Axitinib for Frontline RCC

July 29, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab in combination with axitinib for the frontline treatment of patients with advanced renal cell carcinoma (RCC). The CHMP based its positive opinion on findings from the phase III KEYNOTE-426 trial, which demonstrated that frontline pembrolizumab/axitinib led to a 47% (HR, 0.53; 95% CI, 0.38-0.74; P <.0001) reduction ... (leggi tutto)